PFESeagen, a wholly owned subsidiary of PfizerRunning, no new patients
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Endometrial Neoplasms · Head and Neck Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 120 (final count)
- Started
- Nov 14, 2023
- Main results expected
- Mar 27, 2026
- Fully finished
- May 31, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (ORR) per Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment
Measured over: Approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06003231 · record last updated 2026-07-22 · checked 2026-11-09 15:36 UTC